Regulus

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors

Retrieved on: 
Friday, June 23, 2023

"We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.

Key Points: 
  • "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.
  • "His expertise in nephrology, along with his previous leadership and board experience in the industry, will make him an invaluable member, and we look forward to his contributions to Regulus and our science."
  • Preston Klassen, M.D., recently joined Regulus Therapeutics as President and Head of Research and Development.
  • Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Regulus Therapeutics Strengthens Research & Development Leadership

Retrieved on: 
Monday, June 12, 2023

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of CMC. 

Key Points: 
  • SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development.
  • "We are thrilled to welcome Dr. Klassen to the Regulus team," said Jay Hagan, Chief Executive Officer of Regulus Therapeutics.
  • Dr. Preston Klassen is an established nephrologist who brings years of experience in leadership, medical affairs, and research and development across multiple therapeutic areas.
  • Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Regulus Global Expands Leadership Team with Strategic Medical Executive Paul Ekoniak

Retrieved on: 
Monday, May 15, 2023

VIRGINIA BEACH, Va., May 15, 2023 /PRNewswire/ -- Regulus Global announced today the appointment of Paul Ekoniak as Director, Medical. Ekoniak will lead the company's dynamic solutions capability for global and local medical and expeditionary missions, including humanitarian needs, crisis response and preparedness.

Key Points: 
  • VIRGINIA BEACH, Va., May 15, 2023 /PRNewswire/ -- Regulus Global announced today the appointment of Paul Ekoniak as Director, Medical.
  • "Paul brings first-hand experience and a deep understanding of medical missions and operational preparedness," said Chief Executive Officer Chris Burgess.
  • Ekoniak and the Regulus Global medical team will be available at the Special Operations Medical Association Conference, May 15-19, in Raleigh, North Carolina to meet with customers, partners and business associates.
  • "I am honored to be joining Regulus and highly energized to contribute toward Regulus Global's medical missions – from mobile hospitals in developing countries to equipping first responders and special operations teams," said Medical Director Paul Ekoniak.

Regulus Global Expands Operations in Colombia with American Tactical

Retrieved on: 
Tuesday, February 21, 2023

VIRGINIA BEACH, Va. and BOGOTÁ, Colombia, Feb. 21, 2023 /PRNewswire/ -- Regulus Global announced today that it is expanding operations through a new partner, American Tactical, to increase its presence in the Colombian region.

Key Points: 
  • VIRGINIA BEACH, Va. and BOGOTÁ, Colombia, Feb. 21, 2023 /PRNewswire/ -- Regulus Global announced today that it is expanding operations through a new partner, American Tactical, to increase its presence in the Colombian region.
  • "American Tactical specializes in the optimal supply of quality products to special forces in Colombia and Mexico," said Diego Soler, General Manager of American Tactical.
  • "Regulus Global aligned with American Tactical at SHOT Show 2023 with the intent of building a unique understanding and increased presence in the Colombian region" said Ray Gonzalez, Global Manager of Business Development, Regulus Global.
  • In the last decade, Regulus Global has grown exponentially offering mission solutions in more than 80 countries globally.

Regulus Acquires 70% Interest in Colquirrumi Claims

Retrieved on: 
Wednesday, February 15, 2023

VANCOUVER, British Columbia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Regulus Resources Inc. (“Regulus” or the “Company”, TSX-V: REG, OTCQX: RGLSF) is pleased to announce that it has acquired a 70% interest in the Colquirrumi claims.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Regulus Resources Inc. (“Regulus” or the “Company”, TSX-V: REG, OTCQX: RGLSF) is pleased to announce that it has acquired a 70% interest in the Colquirrumi claims.
  • The Colquirrumi claims will be held by a joint-venture with 70% belonging to Regulus and 30% belonging to Compañía Minera Colquirrumi S.A., a wholly owned subsidiary of Buenaventura (“Buenaventura”).
  • Regulus had the right to earn up to a 70% interest in the claims by completing 7,500 m of drilling.
  • Buenaventura retained a one-time claw-back whereby it could retain a 70% interest in the claims by paying Regulus US$9,000,000 and granting Regulus a 30% interest.

Nuton Acquires Common Shares of Regulus Resources

Retrieved on: 
Monday, January 30, 2023

Pursuant to the Financing, Nuton was issued 20,058,974 common shares in the capital of the Company (each, a “Common Share”) at an issuance price equal to C$1.02 per Common Share.

Key Points: 
  • Pursuant to the Financing, Nuton was issued 20,058,974 common shares in the capital of the Company (each, a “Common Share”) at an issuance price equal to C$1.02 per Common Share.
  • Upon completion of the Financing, Nuton acquired beneficial ownership and control over 20,058,974 Common Shares representing 16.1% of the issued and outstanding Common Shares on completion on a non-diluted basis.
  • In connection with the Financing, Regulus and Nuton have entered into a collaboration agreement wherein Nuton was granted certain investor rights, including allowing Nuton to maintain its equity interest in Regulus if it maintains said interest above 10%.
  • Additionally, Nuton shall be allowed to nominate a director to the board of directors of Regulus.

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Thursday, February 9, 2023

SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .

Key Points: 
  • SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Regulus Therapeutics Inc .
  • (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 1:00 p.m.
  • ET.
  • A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 30 days following the presentation date.

Regulus Grants Incentive Stock Options

Retrieved on: 
Tuesday, February 7, 2023

VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) announces that incentive stock options have been granted to directors, officers, employees and consultants to purchase up to 3,950,000 common shares at a price of $1.02 per share for five years, pursuant to its Stock Option Plan.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) announces that incentive stock options have been granted to directors, officers, employees and consultants to purchase up to 3,950,000 common shares at a price of $1.02 per share for five years, pursuant to its Stock Option Plan.
  • These stock options will vest over a two year period.
  • The Company currently has 124,508,818 shares issued and outstanding, along with 11,725,000 options (including the options described above) and 5,500,000 warrants outstanding.

Regulus Announces Closing of Strategic Investment by Nuton, a Rio Tinto Venture

Retrieved on: 
Monday, January 30, 2023

VANCOUVER, British Columbia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) is pleased to announce it has completed its previously announced non-brokered private placement of 22,658,974 common shares ("Common Shares") at a price of $1.02 per Common Share for total gross proceeds of C$23,112,153 (the "Private Placement"), led by a strategic investment from Nuton LLC, a Rio Tinto Venture ("Nuton") (see news releases dated December 22, 2022 and January 20, 2023).

Key Points: 
  • Nuton acquired 20,058,974 Common Shares for total proceeds of C$20,460,153.
  • Route One Investment Company LLC, Regulus' largest shareholder, has participated in the Private Placement and acquired 2,600,000 Common Shares for total proceeds of C$2,652,000.
  • Regulus intends to use the funds to advance the AntaKori project and for general corporate purposes.
  • The Offering remains subject to final approval from the TSX Venture Exchange.

Regulus Announces Upsizing of Private Placement to C$23.1 Million

Retrieved on: 
Friday, January 20, 2023

VANCOUVER, British Columbia, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Regulus Resources Inc. ("Regulus" or the "Company", TSX-V: REG, OTCQX: RGLSF) is pleased to announce that its non-brokered private placement (the "Private Placement"), previously announced on December 22, 2022, has been upsized to 22,658,974 common shares ("Common Shares") at a price of C$1.02 per Common Share for total gross proceeds of C$23,112,153.

Key Points: 
  • The Company's largest shareholder, Route One Investment Company LLC ("Route One"), has elected to participate in the Private Placement by agreeing to purchase 2,600,000 Common Shares at a price of C$1.02 per share.
  • No finders fee is payable in connection with the Private Placement.
  • Accordingly, the participation of Route One in the Private Placement constitutes a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("61-101").
  • The Company will not file a material change report more than twenty-one (21) days before the expected closing date of the Private Placement as the details of the Private Placement were not finalized until January 19, 2023, and the Company wishes to close the Private Placement as soon as practicable.